Jochen Reiser | |
---|---|
Born | June 23, 1971 53) Pforzheim, Germany | (age
Nationality | American/German |
Alma mater | Ruprecht-Karls-Universität Heidelberg |
Known for | Podocytes, Glomerular diseases, Chronic kidney disease (CKD), Focal segmental glomerulosclerosis (FSGS), Soluble urokinase plasminogen activator receptor (suPAR). |
Awards |
|
Scientific career | |
Fields | Nephrology |
Institutions | University of Texas Medical Branch |
Website | Office of the President - UTMB Health |
Jochen Reiser (born June 23, 1971, in Pforzheim, Germany) is a physician-scientist and a healthcare leader. He is the President of the University of Texas Medical Branch (UTMB) and CEO of the UTMB Health System, [1] which includes the oldest medical school and nursing school in Texas. As chief executive officer, he oversees the enterprise which includes multiple campuses, five health science colleges, the Galveston National Laboratory (BSL-4) and the Correctional Health Care Services for most of Texas.
Prior to joining the University of Texas Medical Branch, he served as the Ralph C Brown Professor and the Chairman of Medicine at Rush University Medical Center. [2] Reiser's research has provided important mechanistic insights into the molecular pathogenesis of kidney diseases.
Reiser discovered the role of suPAR (soluble urokinase plasminogen activator receptor) as a global, circulating risk factor for chronic kidney disease (CKD) [3] and for acute kidney injury (AKI). [4]
suPAR is investigated as potential causative agent contributing to many kidney diseases including focal segmental glomerulosclerosis (FSGS). These studies have broad clinical significance and lay the foundation for creation of novel diagnostics and pharmaco-therapeutics with potential benefit for a large patient population. His studies on suPAR molecule were featured in Science in 2018. [5] Reiser has been an advocate of science and innovation for two decades and was named as an inventor on multiple patents. He is co-founder of Cambridge, Massachusetts-based Walden Biosciences, [6] an ARCH Venture Partners joint-venture biopharmaceutical portfolio company dedicated to develop first-in-class therapeutics for kidney diseases.
Reiser received his medical and Ph.D. degrees from Ruprecht-Karls-Universität Heidelberg in Heidelberg, Germany]], in 1998 and 1999, respectively. His dissertation, summa cum laude, was entitled Pathobiologie der Podozyten: Molekulare Analyse der glomerulären Schlitzmembran und Fortsatzdynamik von Podozyten at the Institute for Anatomy and Cell Biology, [7]
He worked as postdoctoral fellow in Molecular and Cellular Biology and Kidney Disease at Albert Einstein College of Medicine for a year. From 2000 to 2003, he trained in Internal Medicine at Albert Einstein College of Medicine. [8] After his residency (medicine), he did fellowship training in Nephrology at Harvard Medical School-affiliated Massachusetts General Hospital (MGH) [9] and Brigham and Women’s Hospital (BWH). [10]
Reiser’s independent academic career started as an assistant professor at Harvard Medical School in 2005. In 2007, he founded and directed the MGH Program in Glomerular Disease, which runs the first of its kind at a Harvard University-affiliated hospital.
After three years on the faculty of Harvard Medical School, he joined the University of Miami Miller School of Medicine as a professor of anatomy and cell biology. He was also appointed as the Chief of Division of Nephrology and Hypertension [11] and the Director of the Peggy and Harold Katz Family Drug Center Institute at the University of Miami.
In 2010, he was elected as the Vice Chair for Research by the Department of Medicine. [12] In 2011, he took up the role of Endowed (Peggy and Harold Katz) Chair in Vascular Biology and Kidney Disease. In 2012, he was promoted to interim chairman of Medicine at the University of Miami Miller School of Medicine.
After having served in various capacities at the University of Miami, Reiser was appointed as The Ralph C Brown MD Professor and Chairman of Medicine by Rush University Medical Center in September 2012. Reiser’s academic career has centered on his role as Chairman of Medicine at Rush University and he has been a member of Medical Executive Committee (MEC) (2014–2016), Committee on Senior Faculty Appointments and Promotions (COSFAP) (2014, Chair 2015–2016), Committee on Student Evaluation and Promotion (COSEP) (2014–2016), and Conflict of Interest and Commitment Committee (COIIR) (since 2013). He currently serves on the Faculty Council for Rush University.
In May 2023, the University of Texas System Board of Regents appointed Reiser as President of the University of Texas Medical Branch in Galveston and CEO of the UTMB Health System. [13]
Reiser's research focuses on podocyte biology and glomerular diseases. His laboratory [14] has been developing therapies and assays to combat renal diseases and its many complications since 2004.
His contributions range from identification of a common circulating blood protein —soluble urokinase plasminogen activator receptor (suPAR)— in the pathogenesis of focal segmental glomerulosclerosis (FSGS) [15] to suPAR's emerging role as earliest known biomarker for incident and progressive chronic kidney disease (CKD) [3] as well as for acute kidney injury (AKI). [4] suPAR may link the innate immune system functionally to the kidney – a novel, potentially fundamental concept. "suPAR is a global risk factor for kidney diseases and lower levels of it are better for any of them. He also compares the characteristics of suPAR to that of cholesterol. suPAR targeting may do for kidney disease what statins has done for cardiovascular disease", he says. [16] His work has been responsible for new research fields and is significantly sparking new therapeutic approaches for renal diseases.
Reiser has published more than 220 papers, which have received in excess of 21000 citations. [17] He has been involved in editorial activities of various scientific journals including Journal of Clinical Investigation, Journal of the American Society of Nephrology (JASN), Kidney International, American Journal of Therapeutics, International Journal of Nephrology, and F1000Prime.
As a healthcare leader, Reiser engages others to work in a team-focused approach, which drives success and motivation. Forward thinking and disruptive in the idea, he leads with transparency and accountability, applying a data-driven approach to ensure successful navigation through the complex financial and academic world of healthcare today.
Reiser has been an active member of the following prestigious physician societies:
The significance of his work has been recognized by numerous distinctions and awards:
He was awarded visiting professorship or honored as keynote speaker by various universities and institutions including Weill Cornell Medicine (The Rogosin Institute Lecturer; 2013), University of California at Los Angeles (UCLA Kleeman Award, 2013), Peking University First Hospital (2013), University of Mississippi (2014), Brown University (2015), Harvard Medical School (2015), University of Michigan (2016), Johns Hopkins Hospital (2017), University of California San Francisco Medical Center (2017), Yale University (2018), Icahn School of Medicine at Mount Sinai (2019), University of Alabama (2020), Duke University (2021) and National Institutes of Health (Invited National Speaker, 2022).
The University of Texas Medical Branch (UTMB) is a public academic health science center in Galveston, Texas, United States. It is part of the University of Texas System. UTMB includes the oldest medical school in Texas, and has about 11,000 employees. As of April 2024, it had an endowment of $763 million.
The University of Texas Southwestern Medical Center is a public academic health science center in Dallas, Texas. With approximately 23,000 employees, more than 3,000 full-time faculty, and nearly 4 million outpatient visits per year, UT Southwestern is the largest medical school in the University of Texas System and the State of Texas.
Podocytes are cells in Bowman's capsule in the kidneys that wrap around capillaries of the glomerulus. Podocytes make up the epithelial lining of Bowman's capsule, the third layer through which filtration of blood takes place. Bowman's capsule filters the blood, retaining large molecules such as proteins while smaller molecules such as water, salts, and sugars are filtered as the first step in the formation of urine. Although various viscera have epithelial layers, the name visceral epithelial cells usually refers specifically to podocytes, which are specialized epithelial cells that reside in the visceral layer of the capsule.
The Urokinase receptor, also known as urokinase plasminogen activator surface receptor (uPAR) or CD87, is a protein encoded in humans by the PLAUR gene. It is a multidomain glycoprotein tethered to the cell membrane with a glycosylphosphotidylinositol (GPI) anchor. uPAR was originally identified as a saturable binding site for urokinase on the cell surface.
Marilyn Gist Farquhar was a pathologist and cellular biologist, Professor of Cellular and Molecular Medicine and Pathology, as well as the chair of the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine, who previously worked at Yale University from 1973 to 1990. She has won the E. B. Wilson Medal and the FASEB Excellence in Science Award. She was married to Nobel Laureate George Emil Palade from 1970 to his death in 2008. Her research focuses on control of intracellular membrane traffic and the molecular pathogenesis of auto immune kidney diseases. She has yielded a number of discoveries in basic biomedical research including: mechanisms of kidney disease, organization of functions that attach cells to one another, and mechanisms of secretions.
Soluble urokinase plasminogen activator receptor (suPAR) is a protein and the soluble form of uPAR. uPAR is expressed mainly on immune cells, endothelial cells, and smooth muscle cells. uPAR is a membrane-bound receptor for uPA, also known as urokinase and Vitronectin. The soluble version of uPAR, called suPAR, results from the cleavage and membrane-bound uPAR during inflammation or immune activation. The suPAR concentration is positively correlated to the activation level of the immune system. Therefore, suPAR is a marker of disease severity and aggressiveness and is associated with morbidity and mortality in several acute and chronic diseases. suPAR levels have been observed to increase with age. suPAR is present in plasma, urine, blood, serum, and cerebrospinal fluid.
Sharon A. Anderson is an American physician, educator, and researcher practicing in Portland, Oregon. She has contributed extensively to the study of the progression of chronic kidney disease. Her research has focused on diabetic nephropathy, polycystic kidney disease and the pathophysiology of the aging kidney. She was the first woman to serve as President of the American Society of Nephrology (ASN). She was the Chief of the Department of Medicine at the Veteran's Affairs Medical Center in Portland and is currently the Chair of the Department of Medicine at Oregon Health and Science University (OHSU). She has been appointed to the National Institutes of Health Council of Councils. Her publications as author or co-author number greater than 150.
Jochen H.H. Ehrich is a German pediatric doctor in the fields of nephrology and tropical medicine, professor emeritus and Former Head of the Department of Paediatric Kidney, Liver and Metabolic Diseases at the Children’s Hospital, Hannover Medical School, in Hannover, Germany.
Vsevolod Tkachuk is a Soviet and Russian biochemist. Academician of RAMS and RAS. Dean of the Faculty of fundamental medicine of Lomonosov Moscow State University. Director of institute of regenerative medicine in Lomonosov Moscow State University and president of National regenerative medicine society.
Melissa Helen Little is an Australian scientist and academic, currently Theme Director of Cell Biology, heading up the Kidney Regeneration laboratory at the Murdoch Children's Research Institute. She is also a Professor in the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, and Program Leader of Stem Cells Australia. In January 2022, she became CEO of the Novo Nordisk Foundation Center for Stem Cell Medicine reNEW, an international stem cell research center based at University of Copenhagen, and a collaboration between the University of Copenhagen, Denmark, Murdoch Children’s Research Institute, Australia, and Leiden University Medical Center, The Netherlands.
Donald Wayne Seldin was an American nephrologist. He worked at University of Texas Southwestern Medical Center and served as chair of the department of medicine for 36 years.
Minnie M. Sarwal is an adult and pediatric nephrologist, researcher of transplant immunology, and biotechnology entrepreneur in San Francisco. She has made significant contributions to the field of organ transplantation, including conducting the first successful complete steroid avoidance trial in the US and the first dosing safety trial for Rituximab in pediatric renal transplantation. She also spearheaded genomic and proteomics investigations into mechanisms of organ transplant injury and was the first to determine that there was substantive molecular heterogeneity in acute kidney transplant rejection. She has successfully commercialized blood testing for early diagnosis of both acute rejection and operational tolerance in kidney transplant patients, providing tools for proactive and predictive immunosuppression monitoring for transplant recipients.
Lisa Robinson is a Canadian clinician-scientist. She is a University of Toronto professor in the Department of Paediatrics and the Dean of the Temerty Faculty of Medicine, former Head of the Division of Nephrology at The Hospital for Sick Children, a Senior Scientist at the SickKids Research Institute, President American Pediatric Society 2022-2023, and the first-ever Chief Diversity officer for the Faculty of Medicine at University of Toronto.
Vanessa Grubbs is a nephrologist and a writer based in Oakland, California. She is an associate professor at the University of California, San Francisco. She works at Zuckerberg San Francisco General Hospital.
Susan E. Quaggin is a Canadian nephrologist. She is the Charles Horace Mayo Professor of Medicine at Northwestern University Feinberg School of Medicine, Director of the Feinberg Cardiovascular Research Institute and chief of the Division of Nephrology.
Julie Alice Rich Ingelfinger is an American pediatric nephrologist. She is a deputy editor for the New England Journal of Medicine, professor of pediatrics at Harvard Medical School, and consulting pediatric nephrologist at Massachusetts General Hospital.
Paul E. Klotman is an American physician-scientist and academic administrator. He is the president, CEO and executive dean of the Baylor College of Medicine, a position he began on Sept. 1, 2010.
Morgan Erika Grams is an American nephrologist. She is the Co-Director of the Division of Precision Medicine, and the Susan and Morris Mark Professor in the Departments of Medicine and Population Health at NYU Langone Health.
Deidra C. Crews MD, ScM is an American nephrologist and epidemiologist. She is the Deputy Director of Johns Hopkins Center for Health Equity and a Professor of Medicine at Johns Hopkins School of Medicine. Crews research focuses on social drivers of disparities in kidney disease and hypertension.
J. Charles Jennette is a physician, nephropathologist, academic, and author. He served as Kenneth M. Brinkhous Distinguished Professor and Chair of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill School of Medicine, and Chief of Pathology and Laboratory Medicine Services at UNC Hospitals from 1999 to 2019.